Trials / Completed
CompletedNCT04211831
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Urovant Sciences GmbH · Industry
- Sex
- Female
- Age
- 40 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder (OAB) and urge urinary incontinence (UUI) up to 48 weeks post-dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | URO-902 | intradetrusor injection |
| DRUG | Placebo | intradetrusor injection |
Timeline
- Start date
- 2019-12-16
- Primary completion
- 2021-11-18
- Completion
- 2022-07-20
- First posted
- 2019-12-26
- Last updated
- 2023-04-20
- Results posted
- 2023-04-20
Locations
20 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04211831. Inclusion in this directory is not an endorsement.